MedTrace Logo

Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii

NCT01297894 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2011-12-29

No results posted yet for this study

Summary

In Siriraj Hospital, colistin alone for treatment of MDR A. baumannii contributed to mortality 45% Fosfomycin is an antimicrobial which has activity against gram-negative bacterial including MDR A. baumannii In this study, we compare the clinical and microbiologicalresponse of colistin alone versus colistin plus fosfomycin in treatment of A. baumannii infected patients

Conditions

  • Drug Safety

Interventions

DRUG

colistin

Colistimethate sodium 2.5-5mg/kg of colistin base

DRUG

colistin plus fosfomycin

colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Visanu Thamlikitkul, MD · Siriraj Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297894 on ClinicalTrials.gov